10 May 2022: Original Paper
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
Bruno Roche 1BCDE , Artur Bauhofer 2ACDEF* , Miguel Ãngel Gomez Bravo 3BCDE , Georges Philippe Pageaux 4ABCDE , Fabien Zoulim 5BDE , Alejandra Otero 6BC , Martin Prieto 78BC , Carmen Baliellas 9BC , Didier Samuel 1ACDEDOI: 10.12659/AOT.936162
Ann Transplant 2022; 27:e936162
Table 6 HBV and HCC recurrence rates after LT under various prophylactic regimens.
| Author, year [ref] | Patients, N/n (total/HCC) | Prophylactic treatment | Median duration of follow up, (total/HCC) [months] | HBV recurrence (based on HBsAg and/or HBV DNA) N (%)/AR | HCC recurrence n (%)/AR | Comments |
|---|---|---|---|---|---|---|
| Fung et al, 2017 []21 | 242/97 | NUC only (entecavir) | 59/51 | 36 (14.9)/3.03% | 13 (13.4)/3.15% | Only patients with HBsAg clearance post LT included patients with re-transplantation and/or LAM-resistance excluded |
| Beckebaum et al, 2018 []14 | 371/147 | HBIg+NUC | 84/67 | 16 (4.3)/0.65% | 14 (9.5)/1.7% | Patients outside the Milan Criteria excluded |
| Lens et al, 2018 []22 | 338/113 | HBIg+NUC | 72/71.8 | 37 (11.0)/1.83% | 15 (13.3)/2.17% | Patients with short- and long-term HBIg treatment |
| Current study | 195/83 | sc HBIg+NUC | 24/20.5 | 7 (3.6)/2.01% | 4 (4.8)/2.88% | High variability regarding time to first sc HBIg treatment after LT – from days to years |
| AR – annual rate; HBIg – hepatitis B immunoglobulin; HCC – hepatocellular carcinoma; LAM – lamivudine; LT – liver transplantation; N – all study patients (total); n – subgroup of patients with HCC at time of LT; NUC – nucleos(t)ide analog. | ||||||